TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03362437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Form A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Form B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Form B
Study: NCT01822600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels \< 25 g/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up.
Study: NCT03429192

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgeries plus dissection of lymph nodes
Study: NCT01926548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ Imatinib mesylate tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gleevec film-coated tablet 2 x 100mg
Study: NCT02435225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction for Teens Group
Description: A 12-Week weekly group intervention to train adolescents in mindfulness practice
Study: NCT02456779

Intervention type: OTHER
Intervention: in vitro diagnostic test (Peptest)
Description: saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest

Intervention type: OTHER
Intervention: in vitro diagnostic test (Peptest)
Description: saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest

Intervention type: OTHER
Intervention: in vitro diagnostic test (Peptest)
Description: saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest

Intervention type: OTHER
Intervention: Questionnaire
Description: all recruited subjects to complete the RDQ as a determinant of inclusion criteria
Study: NCT00866138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: masitinib 9 mg/kg/day per os
Study: NCT01325428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib once daily (OD)
Description: Patient to receive afatinib monotherapy until progression of their disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Weekly
Description: Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
Study: NCT00892632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP and Confocal imaging
Description: A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
Study: NCT00725075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8435 (Org 25935) 4-8 mg
Description: Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for MK-8435 (Org 25935) administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8435 (Org 25935) 12-16 mg
Description: Administered orally BID for a final concentration of 24-32 mg/day
Study: NCT00876135

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ventolin
Description: Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
Study: NCT05749380

Intervention type: DRUG
Group type: OTHER
Intervention: AmBisome
Description: Reference, dose of 3 mg/kg.

Intervention type: DRUG
Group type: OTHER
Intervention: AmBisome
Description: Reference, dose of 3 mg/kg.

Intervention type: DRUG
Group type: OTHER
Intervention: AmBisome
Description: Reference, dose of 3 mg/kg.

Intervention type: DRUG
Group type: OTHER
Intervention: AmBisome
Description: Reference, dose of 3 mg/kg.

Intervention type: DRUG
Group type: OTHER
Intervention: DKF-5122
Description: Test, dose of 3 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: DKF-5122
Description: Test, dose of 3 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: DKF-5122
Description: Test, dose of 3 mg/kg
Study: NCT02456779

Intervention type: OTHER
Intervention: Questionnaire
Description: all recruited subjects to complete the RDQ as a determinant of inclusion criteria
Study: NCT05749380

Intervention type: DRUG
Group type: OTHER
Intervention: DKF-5122
Description: Test, dose of 3 mg/kg
Study: NCT03713944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15mg/kg
Study: NCT02184871

Intervention type: OTHER
Intervention: exposure to different risk factors and molecular assessment
Study: NCT02090400

Intervention type: DRUG
Group type: OTHER
Intervention: Bazedoxifene
Description: 20 mg Oral daily for 12 months

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium/Vit D
Description: Calcium 500 mg / 400 IU Vit D

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium/Vit D
Description: Calcium 500 mg / 400 IU Vit D
Study: NCT01975012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules \[2.5 mg/g\]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules \[2.5 mg/g\]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available.
Study: NCT01908660

Intervention type: DRUG
Intervention: antiretroviral drugs
Description: zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
Study: NCT00280007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
Study: NCT01278498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: first week:5mg 2nd week\~12 week:10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: first week:5mg 2nd week\~12 weeks:10mg
Study: NCT02223572

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hip Xray
Study: NCT04017143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV app intervention
Description: Participants assigned to this group will receive an HPV app that targets a dyad of parent and a teen boy or girl.
Study: NCT03227705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prometrium
Description: Intravaginal use, off label, of Prometrium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prometrium
Description: Intravaginal use, off label, of Prometrium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dr. Arabin, cerclage pessary perforated
Description: A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
Study: NCT01309178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannite
Description: Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
Study: NCT04063371

Intervention type: OTHER
Intervention: Self-Administered Gerocognitive Examination (SAGE) or Electronic Self-Administered Gerocognitive Examination (eSAGE)
Description: The Self-Administered Gerocognitive Examination (SAGE) is a reliable and valid assessment that is used to detect MCI and early dementia. It is a pen and paper assessment that has 4 interchangeable versions. The digital version of SAGE (eSAGE; commercially known as BrainTest®) is made for tablet use, consists of the identical test questions as SAGE, and is strongly associated with the validated SAGE.

Intervention type: OTHER
Intervention: Informant Conversation
Description: If possible, the provider will have a conversation with an individual who knows the patient will to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
Study: NCT01024998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-sFLT01
Description: 2 x 10\^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-sFLT01
Description: 2 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-sFLT01
Description: 6 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-sFLT01
Description: 2 x 10\^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
Study: NCT03993184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hot Yoga
Description: Bikram or hot yoga is a standardized series of 26 postures with two breathing exercises. Classes will be performed at local yoga studios in Austin, Texas and participants will be required to sign in for each session. All participants will receive 12 weeks of free classes for their participation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hot Yoga
Description: Bikram or hot yoga is a standardized series of 26 postures with two breathing exercises. Classes will be performed at local yoga studios in Austin, Texas and participants will be required to sign in for each session. All participants will receive 12 weeks of free classes for their participation.
Study: NCT03039842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan+memantine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+valproate
Study: NCT03609307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Intravitreal bevacizumab and propranolol
Description: these patients receive two injections at each session Bavacizumab and propranolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab
Description: these patients receive only Bevacizumab
Study: NCT02698488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphology

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphology

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphology and Mass Spectroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphology and Mass Spectroscopy
Study: NCT03505229

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Stereotactic Body Radiotherapy (SBRT) 30-45 gray in 5 fractions over 2 weeks will be given to all eligible patients.
Study: NCT03493217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: The drug product is a white, round, uncoated tablet.
Study: NCT02333617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point \[No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)\]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Mobilization
Description: Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
Study: NCT01477242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 2mg (5mL) in \< 15 kg and 4mg (10mL) in 15kg to 30kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 2mg (5mL) in \< 15 kg and 4mg (10mL) in 15kg to 30kg
Study: NCT02271503

Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: IPX203 180 mg
Description: IPX203 containing 45 mg carbidopa and180 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: IPX203 180 mg
Description: IPX203 containing 45 mg carbidopa and180 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: IPX203 180 mg
Description: IPX203 containing 45 mg carbidopa and180 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: IPX203 270 mg
Description: IPX203 containing 67.5 mg carbidopa and 270 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: IPX203 270 mg
Description: IPX203 containing 67.5 mg carbidopa and 270 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: IPX203 270 mg
Description: IPX203 containing 67.5 mg carbidopa and 270 mg levodopa

Intervention type: DRUG
Group type: OTHER
Intervention: Rytary 195 mg
Description: Rytary 48.75Mg-195Mg Extended-Release Capsule

Intervention type: DRUG
Group type: OTHER
Intervention: Rytary 195 mg
Description: Rytary 48.75Mg-195Mg Extended-Release Capsule

Intervention type: DRUG
Group type: OTHER
Intervention: Rytary 195 mg
Description: Rytary 48.75Mg-195Mg Extended-Release Capsule

Intervention type: DRUG
Group type: OTHER
Intervention: Rytary 145 mg
Description: Rytary 36.25Mg-145Mg Extended-Release Capsule

Intervention type: DRUG
Group type: OTHER
Intervention: Rytary 145 mg
Description: Rytary 36.25Mg-145Mg Extended-Release Capsule

Intervention type: DRUG
Group type: OTHER
Intervention: Rytary 145 mg
Description: Rytary 36.25Mg-145Mg Extended-Release Capsule
Study: NCT02207933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AP shifting training
Description: AP shifting training in addition to gait training 3 times a week for 6 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: Gait training only for 3 times a week for 6 weeks.
Study: NCT03195907

Intervention type: OTHER
Intervention: Pulmonary physiotherapy
Study: NCT00487539

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -\> 50 mg arm group and at Week 2 for Golimumab 200 mg -\> 100 mg arm group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -\> 50 mg arm group and at Week 2 for Golimumab 200 mg -\> 100 mg arm group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 200 mg
Description: Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -\> 100 mg arm group and at Week 2 for Golimumab 400 mg -\> 200 mg arm group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 200 mg
Description: Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -\> 100 mg arm group and at Week 2 for Golimumab 400 mg -\> 200 mg arm group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 400 mg
Description: Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -\> 200 mg arm group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -\> 50 mg arm group.
Study: NCT03655964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No antihypertensive treatment
Description: Patients will be left without treatment
Study: NCT02813200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide® Diskus® 500/550 μg
Description: Every day during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide® Diskus® 500/550 μg
Description: Every day during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide® Diskus® 500/550 μg
Description: Every day during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultibro® Breezhaler® 110/50 μg
Description: Every day during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultibro® Breezhaler® 110/50 μg
Description: Every day during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultibro® Breezhaler® 110/50 μg
Description: Every day during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva® Respimat® 2,5 μg
Description: Every day during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva® Respimat® 2,5 μg
Description: Every day during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva® Respimat® 2,5 μg
Description: Every day during 7 days
Study: NCT03592446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical vagus nerve stimulation
Description: All subjects receive electrical VNS stimulation at cymba conchae.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: All subjects receive electrical stimulation at earlobe.
Study: NCT00229307

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure (PE) therapy
Description: 20 minutes exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure (PE) therapy
Description: 40 minutes exposure
Study: NCT04113772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: Measure bio equivalency/efficacy of nitinosine and orfadin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orfadin
Description: Orfadin